Recent publications:
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
Suthar MS, Manning KE, Ellis ML, Jain S, Bechnak K, Vander Velden J, Laboune F, Henry AR, Godbole S, Kim S, Sahoo MK, Paredes I, Dib SM, Kalash S, Radi C, Hicks H, Tamin A, Gardner M, Bowen N, Cook P, Paden C, Harcourt J, Pinsky BA, Douek DC, Rouphael N, Moreno A.
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories.
Brangel P, Tureli S, Mühlemann B, Liechti N, Zysset D, Engler O, Hunger-Glaser I, Ghiga I, Mattiuzzo G, Eckerle I, Bekliz M, Rössler A, Schmitt MM, Knabl L, Kimpel J, Tort LFL, de Araujo MF, de Oliveira ACA, Caetano BC, Siqueira MM, Budt M, Gensch JM, Wolff T, Hassan T, Selvaraj FA, Hermanus T, Kgagudi P, Crowther C, Richardson SI, Bhiman JN, Moore PL, Cheng SMS, Li JKC, Poon LLM, Peiris M, Corman VM, Drosten C, Lai L, Hunsawong T, Rungrojcharoenkit K, Lohachanakul J, Sigal A, Khan K, Thiel V, Barut GT, Ebert N, Mykytyn AZ, Owusu Donkor I, Aboagye JO, Nartey PA, Van Kerkhove MD, Cunningham J, Haagmans BL, Suthar MS, Smith D, Subissi L.
Tissue-resident memory T cells contribute to protection against heterologous SARS-CoV-2 challenge.
Odle A, Kar M, Verma AK, Sariol A, Meyerholz DK, Suthar MS, Wong LR, Perlman S.
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.
Rostad CA, Yildirim I, Kao C, Yi J, Kamidani S, Peters E, Stephens K, Gibson T, Hsiao HM, Singh K, Spearman P, McCracken C, Agbakoba V, Tomashek KM, Goll JB, Gelber CE, Johnson RA, Lee S, Maner-Smith K, Bosinger S, Ortlund EA, Chen X, Anderson LJ, Wrammert J, Suthar M, Rouphael N, Anderson EJ.
The Interplay Between Evolution and Host Immunity.
Case JB, Jain S, Suthar MS, Diamond MS.
Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.
Munoz FM, Beigi R, Posavad CM, Kelly C, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Richardson BA, Olsen-Chen C, Novak RM, Brady RC, DeFranco E, Gerber JS, Shriver M, Suthar MS, Coler R, Berube BJ, Kim SH, Piper JM, Miedema J, Pasetti M, Neuzil KM, Cardemil CV; DMID Study Group.
Divergence of variant antibodies following SARS-CoV-2 booster Vaccines in myeloma and impact of hybrid immunity.
Moreno A, Manning K, Azeem MI, Nooka AK, Ellis M, Manalo RJ, Switchenko JM, Wali B, Kaufman JL, Hofmeister CC, Joseph NS, Lonial S, Dhodapkar KM, Dhodapkar MV, Suthar MS.
A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo.
Misasi J, Wei RR, Wang L, Pegu A, Wei CJ, Oloniniyi OK, Zhou T, Moliva JI, Zhao B, Choe M, Yang ES, Zhang Y, Boruszczak M, Chen M, Leung K, Li J, Yang ZY, Andersen H, Carlton K, Godbole S, Harris DR, Henry AR, Ivleva VB, Lei QP, Liu C, Longobardi L, Merriam JS, Nase D, Olia AS, Pessaint L, Porto M, Shi W, Wallace SM, Wolff JJ, Douek DC, Suthar MS, Gall JG, Koup RA, Kwong PD, Mascola JR, Nabel GJ, Sullivan NJ.
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
Soudani N, Bricker TL, Darling T, Seehra K, Patel N, Guebre-Xabier M, Smith G, Davis-Gardner M, Suthar MS, Ellebedy AH, Boon ACM.
